Description
Product details
ST-GLIPTIN M 50/500 Sitagliptin (50mg), Metformin SR 500 Introduction: Diabetes mellitus is a chronic condition characterized by elevated blood sugar levels, necessitating effective management strategies to prevent complications and improve quality of life. Sitagliptin and metformin are two commonly prescribed medications for type 2 diabetes mellitus (T2DM), each offering unique mechanisms of action. ST-GLIPTIN M 50/500, a fixed-dose combination tablet containing sitagliptin (50mg) and metformin sustained-release (SR) 500mg, provides a comprehensive approach to glycemic control. This article explores the features, efficacy, safety profile, and clinical implications of ST-GLIPTIN M 50/500 in the treatment of T2DM. Understanding Sitagliptin and Metformin SR: Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and decreases glucagon levels, thereby improving glycemic control. Metformin, a biguanide medication, primarily reduces hepatic glucose production, enhances peripheral glucose uptake, and improves insulin sensitivity. The sustained-release formulation of metformin allows for once-daily dosing, reducing the risk of gastrointestinal side effects commonly associated with immediate-release formulations. Key Features of ST-GLIPTIN M 50/500: ST-GLIPTIN M 50/500 is a fixed-dose combination tablet containing sitagliptin (50mg) and metformin SR 500mg in a standardized formulation. This combination offers the convenience of administering two effective antidiabetic agents in a single tablet, simplifying medication regimens and enhancing patient adherence. The complementary mechanisms of action of sitagliptin and metformin SR provide comprehensive glycemic control, addressing both fasting and postprandial hyperglycemia. Efficacy in Glycemic Control: Clinical studies have demonstrated the efficacy of ST-GLIPTIN M 50/500 in improving glycemic control in patients with T2DM. The combination of sitagliptin and metformin SR has been shown to reduce hemoglobin A1c (HbA1c) levels, fasting plasma glucose, and postprandial glucose excursions, leading to improvements in overall glucose regulation. Additionally, the sustained-release formulation of metformin minimizes fluctuations in drug levels and may improve tolerability compared to immediate-release formulations. Safety Profile: ST-GLIPTIN M 50/500 exhibits a favorable safety profile, with adverse effects typically mild to moderate in severity. Common side effects may include gastrointestinal symptoms such as nausea, diarrhea, or abdominal discomfort, which are often transient and diminish with continued use. Serious adverse events with ST-GLIPTIN M 50/500 are rare, and it is generally well-tolerated by most patients. For further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 https://www.sterisonline.com/product/st-gliptin-m-50-500-134013
